AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14982688 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion hydrochloride sustained-release (Zyban)
Number of subjects: 336
Study 14982688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study 11300658 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg
Number of subjects: 42
Study 11300658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 11300658 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (various doses: 5, 25, 50, 75, 100, 150, or 300 mg)
Number of subjects: 42
Study 11300658 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 42
Study 9428465 — intervention group
Group type: EXPERIMENTAL
Intervention: Predialysis blood draw
Number of subjects: 15000
Study 9428465 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdialysis blood draw
Number of subjects: 15000
Study 9428465 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilution of predialysis sample with heparin or saline
Number of subjects: 15000
Study 9428465 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of access-derived, recirculated blood in postdialysis sample
Number of subjects: 15000
Study 9428465 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive delay in drawing postdialysis sample
Number of subjects: 15000
Study 9428465 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniform blood sample draw procedure
Number of subjects: 15000
Study 7978469 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine (1 mg/kg)
Number of subjects: 48
Study 7978469 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.4 mg/kg
Number of subjects: 48
Study 7978469 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.8 mg/kg
Number of subjects: 48
Study 7978469 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 1.2 mg/kg
Number of subjects: 48
Study 7978469 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine
Number of subjects: 48
Study 2688507 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEpo) at 300 or 150 U/kg body weight, reduced to 75 U/kg
Number of subjects: 333
Study 2688507 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEpo) therapy
Number of subjects: 333
Study 985045 — intervention group
Group type: EXPERIMENTAL
Intervention: Stressful events (both positive and negative valence)
Number of subjects: 0
Study 985045 — intervention group
Group type: EXPERIMENTAL
Intervention: Stressful events (positive emotions)
Number of subjects: 0
Study 985045 — intervention group
Group type: EXPERIMENTAL
Intervention: Stressful events (dysphoric affects)
Number of subjects: 0
Study 31490376 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG combined with carbon nanoparticles (CNs)
Number of subjects: 100
Study 31490376 — intervention group
Group type: COMPARATOR
Intervention: Only carbon nanoparticles (CNs)
Number of subjects: 100
Study 28215212 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm oil (PO) meal
Number of subjects: 40
Study 28215212 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice bran meal
Number of subjects: 40
Study 28215212 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut oil meal
Number of subjects: 40
Study 28215212 — intervention group
Group type: COMPARATOR
Intervention: Isoenergetic meals
Number of subjects: 40
Study 25745071 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular defibrillator (CRT-D)
Number of subjects: 74
Study 25745071 — intervention group
Group type: COMPARATOR
Intervention: Implantable single or dual-chamber defibrillator (ICD)
Number of subjects: 74
Study 23768736 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerochamber with Combivent (200 mcg salbutamol and 20 mcg ipratropium per puff)
Number of subjects: 41
Study 23768736 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulizer with Combivent (2.5 mg salbutamol and 250 mcg ipratropium per mL)
Number of subjects: 41
Study 21594832 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid coronary artery revascularisation (HCR)
Number of subjects: 0
Study 21594832 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical revascularisation (CABG)
Number of subjects: 0
Study 20166337 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined physician-plus-patient intervention
Number of subjects: 417
Study 20166337 — intervention group
Group type: COMPARATOR
Intervention: Physician-only intervention
Number of subjects: 417
Study 16384759 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination clindamycin (1%) and tretinoin (0.025%) hydrogel
Number of subjects: 2219
Study 16384759 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin
Number of subjects: 2219
Study 16384759 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin
Number of subjects: 2219
Study 16384759 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 2219
Study 15597653 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally tubeless PCNL
Number of subjects: 43
Study 15597653 — intervention group
Group type: COMPARATOR
Intervention: PCNL with ureteral stent and nephrostomy tube
Number of subjects: 43
Study 11397861 — intervention group
Group type: EXPERIMENTAL
Intervention: rhLH (5,000, 15,000, 30,000, or 15,000 + 10,000 IU)
Number of subjects: 259
Study 11397861 — intervention group
Group type: COMPARATOR
Intervention: u-hCG (5,000 IU)
Number of subjects: 259
Study 11397861 — intervention group
Group type: EXPERIMENTAL
Intervention: rhLH (up to 30,000 IU)
Number of subjects: 259
Study 11397861 — intervention group
Group type: EXPERIMENTAL
Intervention: rhLH (15,000 to 30,000 IU)
Number of subjects: 259
Study 9024024 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle aperture oriented in a cephalad direction (Group I)
Number of subjects: 40
Study 9024024 — intervention group
Group type: COMPARATOR
Intervention: Needle aperture directed caudally (Group II)
Number of subjects: 40
Study 8360134 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluconazole (50 mg/day as a single dose)
Number of subjects: 536
Study 8360134 — intervention group
Group type: COMPARATOR
Intervention: Oral polyenes (amphotericin B 2 g/day and/or nystatin 4 x 10(6) units/day in four or more divided doses)
Number of subjects: 536
Study 8360134 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluconazole
Number of subjects: 536
Study 8360134 — intervention group
Group type: COMPARATOR
Intervention: Oral polyenes
Number of subjects: 536
Study 3090906 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG) at doses up to 40 micrograms X kg‐1 X min‐1
Number of subjects: 14
Study 3090906 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) at doses of 6‐8 micrograms X kg‐1 X min‐1
Number of subjects: 14
Study 3090906 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 14
Study 3090906 — intervention group
Group type: EXPERIMENTAL
Intervention: Both NTG and SNP
Number of subjects: 14
Study 31465156 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi therapy (Sun style Tai Chi exercise, 5 min warm-up, 45 min main exercise, 10 min meditation, conducted twice a week for 40 sessions over 5 months)
Number of subjects: 104
Study 29229363 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil (FO), 25 mL/d
Number of subjects: 60
Study 29229363 — intervention group
Group type: COMPARATOR
Intervention: Sunflower seed oil (SO), 25 mL/d
Number of subjects: 60
Study 26945711 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir monotherapy
Number of subjects: 0
Study 26945711 — intervention group
Group type: COMPARATOR
Intervention: Atazanavir/ritonavir triple therapy
Number of subjects: 0
Study 24304412 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release oral morphine (SROM)
Number of subjects: 157
Study 24304412 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 157
Study 24304412 — intervention group
Group type: COMPARATOR
Intervention: SROM and Methadone
Number of subjects: 157
Study 21633047 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose XT (capecitabine 1250 mg/m² twice daily, days 1-14; docetaxel 75 mg/m², day 1 every 3 weeks)
Number of subjects: 470
Study 21633047 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose XT (capecitabine 825 mg/m² twice daily, days 1-14; docetaxel as above)
Number of subjects: 470
Study 20731878 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical phenytoin 0.5%
Number of subjects: 100
Study 20731878 — intervention group
Group type: COMPARATOR
Intervention: Cream (control)
Number of subjects: 100
Study 19008797 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromidin
Number of subjects: 55
Study 19008797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 15875094 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct access DXA scanning (DADS)
Number of subjects: 325
Study 15875094 — intervention group
Group type: COMPARATOR
Intervention: Referral to a hospital consultant
Number of subjects: 325
Study 12867219 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (1 tablet BID)
Number of subjects: 94
Study 12867219 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 94
Study 12867219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 11955025 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable model involving readily available clinical variables
Number of subjects: 2903
Study 11955025 — intervention group
Group type: COMPARATOR
Intervention: 2-hour glucose value alone
Number of subjects: 2903
Study 11955025 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable model with 2-hour glucose measurement
Number of subjects: 2903
Study 9734494 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 529
Study 9734494 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 529
Study 9734494 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (for hepatitis C-positive patients)
Number of subjects: 529
Study 9734494 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (for hepatitis C-positive patients)
Number of subjects: 529
Study 8166033 — intervention group
Group type: EXPERIMENTAL
Intervention: Mylanta Cherry Creme
Number of subjects: 30
Study 8166033 — intervention group
Group type: EXPERIMENTAL
Intervention: Mylanta Double Strength Cool Mint Creme
Number of subjects: 30
Study 8166033 — intervention group
Group type: EXPERIMENTAL
Intervention: Riopan Plus 2
Number of subjects: 30
Study 8166033 — intervention group
Group type: EXPERIMENTAL
Intervention: Di‐Gel Lemon Orange
Number of subjects: 30
Study 2975204 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol (0.1 mg orally, twice daily)
Number of subjects: 20
Study 2975204 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (4 mg orally, 3-times a day)
Number of subjects: 20
Study 2975204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31135883 — intervention group
Group type: EXPERIMENTAL
Intervention: Omit NRTIs
Number of subjects: 360
Study 31135883 — intervention group
Group type: COMPARATOR
Intervention: Add NRTIs
Number of subjects: 360
Study 31135883 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized regimen including NRTIs (for highly resistant group)
Number of subjects: 360
Study 31205205 — intervention group
Group type: EXPERIMENTAL
Intervention: Pesticide safety curriculum
Number of subjects: 127
Study 31205205 — intervention group
Group type: COMPARATOR
Intervention: Attention placebo-controlled curriculum (heat illness)
Number of subjects: 127
Study 31205205 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat illness curriculum
Number of subjects: 127
Study 28857895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap-assisted water exchange (CWE)
Number of subjects: 120
Study 28857895 — intervention group
Group type: COMPARATOR
Intervention: Water exchange (WE)
Number of subjects: 120
Study 25937155 — intervention group
Group type: EXPERIMENTAL
Intervention: Single incision laparoscopic varicocelectomy (SIL‐V)
Number of subjects: 80
Study 25937155 — intervention group
Group type: COMPARATOR
Intervention: Conventional transperitoneal varicocelectomy (CTL‐V)
Number of subjects: 80
Study 24135218 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of angiotensin‐converting enzyme inhibitor and angiotensin receptor blocker
Number of subjects: 103
Study 24135218 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with either angiotensin‐converting enzyme inhibitor or angiotensin receptor blocker
Number of subjects: 103
Study 21438793 — intervention group
Group type: EXPERIMENTAL
Intervention: fenofibric acid + moderate-dose statin
Number of subjects: 0
Study 21438793 — intervention group
Group type: EXPERIMENTAL
Intervention: fenofibric acid + low-dose statin
Number of subjects: 0
Study 21438793 — intervention group
Group type: EXPERIMENTAL
Intervention: fenofibric acid + low- and moderate-dose statin
Number of subjects: 0
Study 19130162 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented hemiarthroplasty
Number of subjects: 220
Study 19130162 — intervention group
Group type: COMPARATOR
Intervention: Uncemented hemiarthroplasty
Number of subjects: 220
Study 19130162 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented and uncemented groups
Number of subjects: 220
Study 16780234 — intervention group
Group type: EXPERIMENTAL
Intervention: HYB (hybrid program)
Number of subjects: 20
Study 16780234 — intervention group
Group type: COMPARATOR
Intervention: WT (isotonic weight training)
Number of subjects: 20
Study 16780234 — intervention group
Group type: COMPARATOR
Intervention: ES (isometric electrical stimulation)
Number of subjects: 20
Study 15308255 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplantation into prepared sockets
Number of subjects: 85
Study 15308255 — intervention group
Group type: COMPARATOR
Intervention: Control group (transplantation into fresh extraction site)
Number of subjects: 85
Study 15308255 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplantation with free bone autografts
Number of subjects: 85
Study 15308255 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplantation after splitting osteotomy of the alveolar process
Number of subjects: 85
Study 11296183 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (n = 46)
Number of subjects: 99
Study 11296183 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (n = 53)
Number of subjects: 99
Study 11296183 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (short sedation stratum, n = 21)
Number of subjects: 99
Study 11296183 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (short sedation stratum, n = 26)
Number of subjects: 99
Study 11296183 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (long sedation stratum, n = 4)
Number of subjects: 99
Study 11296183 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (long sedation stratum, n = 10)
Number of subjects: 99
Study 9678089 — intervention group
Group type: EXPERIMENTAL
Intervention: Gracial (DSG/EE 7 x 25/40 micrograms/day + 15 x 125/30 micrograms/day)
Number of subjects: 20
Study 9678089 — intervention group
Group type: COMPARATOR
Intervention: Trigynon (LNG/EE 6 x 50/30 micrograms/day + 5 x 75/40 micrograms/day + 10 x 125/30 micrograms/day)
Number of subjects: 20
Study 9678089 — intervention group
Group type: EXPERIMENTAL
Intervention: Gracial (DSG/EE)
Number of subjects: 20
Study 9678089 — intervention group
Group type: COMPARATOR
Intervention: Trigynon (LNG/EE)
Number of subjects: 20
Study 8314411 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide (1.2 g/m2 body surface)
Number of subjects: 0
Study 8314411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31821997 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt containing Bifidobacterium lactis Bb12
Number of subjects: 66
Study 31821997 — intervention group
Group type: COMPARATOR
Intervention: Conventional yogurt
Number of subjects: 66
Study 31577697 — intervention group
Group type: EXPERIMENTAL
Intervention: YGJT (3g twice a day for 4 weeks) + nutrition counseling
Number of subjects: 52
Study 31577697 — intervention group
Group type: COMPARATOR
Intervention: Nutrition counseling
Number of subjects: 52
Study 27324175 — intervention group
Group type: EXPERIMENTAL
Intervention: Deproteinized porcine bone mineral (DPBM)
Number of subjects: 16
Study 27324175 — intervention group
Group type: COMPARATOR
Intervention: Demineralized bovine bone mineral (DBBM)
Number of subjects: 16
Study 26112886 — intervention group
Group type: EXPERIMENTAL
Intervention: LY518674 100 μg daily
Number of subjects: 28
Study 26112886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 23442225 — intervention group
Group type: EXPERIMENTAL
Intervention: VA (2000 IU daily retinol)
Number of subjects: 400
Study 23442225 — intervention group
Group type: EXPERIMENTAL
Intervention: VD (400 IU daily cholecalciferol)
Number of subjects: 400
Study 23442225 — intervention group
Group type: EXPERIMENTAL
Intervention: VAD (2000 IU daily retinol plus 400 IU cholecalciferol)
Number of subjects: 400
Study 23442225 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 400
Study 21466079 — intervention group
Group type: EXPERIMENTAL
Intervention: Video condition (participants who watched a video of their precompetition preparation)
Number of subjects: 38
Study 21466079 — intervention group
Group type: COMPARATOR
Intervention: No-video condition (players who did not watch a videotape)
Number of subjects: 38
Study 18291727 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral or high-thoracic epidural analgesia combined with sedation or light anesthesia
Number of subjects: 1100
Study 18291727 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anesthesia and morphine analgesia
Number of subjects: 1100
Study 16878680 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri formulation LR-1 (2 x 10(8) CFU per day)
Number of subjects: 59
Study 16878680 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri formulation LR-2 (2 x 10(8) CFU per day)
Number of subjects: 59
Study 16878680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 12874466 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium bicarbonate (0.9 g thrice daily)
Number of subjects: 60
Study 12874466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10672134 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium supplementation (magnesium sulphate 8 g in 250 mL of 5% glucose)
Number of subjects: 68
Study 10672134 — intervention group
Group type: COMPARATOR
Intervention: Placebo (250 mL of 5% glucose)
Number of subjects: 68
Study 9083599 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior skills training intervention (BST)
Number of subjects: 117
Study 9083599 — intervention group
Group type: COMPARATOR
Intervention: Educational intervention (EC)
Number of subjects: 117
Study 8410923 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 27
Study 8410923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 8410923 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril vs Placebo
Number of subjects: 27
Study 3776903 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal 5-FU
Number of subjects: 66
Study 3776903 — intervention group
Group type: COMPARATOR
Intervention: Intravenous 5-FU
Number of subjects: 66
Study 3776903 — intervention group
Group type: COMPARATOR
Intervention: Intravenous 5-FU with pelvic irradiation
Number of subjects: 66
Study 3776903 — intervention group
Group type: EXPERIMENTAL
Intervention: Both routes of administration
Number of subjects: 66
Study 31917837 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive men
Number of subjects: 4994
Study 31917837 — intervention group
Group type: COMPARATOR
Intervention: HIV-negative men
Number of subjects: 4994
Study 31917837 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 4994
Study 31917837 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection drug use
Number of subjects: 4994
Study 31917837 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV infection
Number of subjects: 4994
Study 28970291 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPS (transjugular intrahepatic portosystemic shunt)
Number of subjects: 49
Study 28970291 — intervention group
Group type: COMPARATOR
Intervention: EBL plus propranolol (EBL+drug)
Number of subjects: 49
Study 27495269 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared laser moxibustion
Number of subjects: 78
Study 27495269 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (placebo)
Number of subjects: 78
Study 24842135 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac output-guided hemodynamic therapy algorithm for intravenous fluid and inotrope (dopexamine) infusion during and 6 hours following surgery (n=368)
Number of subjects: 734
Study 24842135 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=366)
Number of subjects: 734
Study 24842135 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of 38 trials including this study
Number of subjects: 734
Study 23021114 — intervention group
Group type: EXPERIMENTAL
Intervention: Screw‐based dental distractor
Number of subjects: 30
Study 23021114 — intervention group
Group type: COMPARATOR
Intervention: Continuous force coil spring distractor
Number of subjects: 30
Study 20573348 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus (40 mg vaginal application once weekly for 6 months)
Number of subjects: 49
Study 20573348 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (500 mg oral treatment twice daily for 7 days)
Number of subjects: 49
Study 17971530 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD (cyclophosphamide, vincristine, and dexamethasone)
Number of subjects: 150
Study 17971530 — intervention group
Group type: EXPERIMENTAL
Intervention: KA/VE (ketoconazole plus doxorubicin alternating with vinblastine plus estramustine)
Number of subjects: 150
Study 17971530 — intervention group
Group type: EXPERIMENTAL
Intervention: TEC (weekly paclitaxel, estramustine, and carboplatin)
Number of subjects: 150
Study 17971530 — intervention group
Group type: EXPERIMENTAL
Intervention: TEE (paclitaxel, estramustine, and etoposide)
Number of subjects: 150
Study 17971530 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line regimens (CVD, KA/VE, TEC)
Number of subjects: 150
Study 17971530 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all treatments)
Number of subjects: 150